Ascendis Pharma A/S (ASND) Goes Over Week 52 Topline Arise From Train Test Examining TransCon CNP and Development Hormonal Agent in Achondroplasia January 8, 2026 4:30 PM EST
Firm Individuals
Scott Smith – CFO, Exec VP & & Participant of Exec Board
Jan Mikkelsen – Head Of State, CHIEF EXECUTIVE OFFICER, Participant of Exec Board & & Exec Supervisor
Aimee Shu – Exec VP & & Principal Medical Police Officer
Teleconference Individuals
Tazeen Ahmad – BofA Stocks, Research Study Department
Joseph Schwartz – Leerink Allies LLC, Research Study Department
Li Wang Watsek – Cantor Fitzgerald & & Co., Research Study Department
Gabriella Garr – TD Cowen, Research Study Department
Maxwell Skor – Morgan Stanley, Research Study Department
Kyuwon Choi – Goldman Sachs Team, Inc., Research Study Department
Gavin Clark-Gartner – Evercore ISI Institutional Equities, Research Study Department
Yun Zhong – Wedbush Stocks Inc., Research Study Department
Alexander Thompson – Stifel, Nicolaus & & Firm, Incorporated, Research Study Department
Luca Issi – RBC Resources Markets, Research Study Department
Derek Archila – Wells Fargo Stocks, LLC, Research Study Department
Discussion
Driver
Thanks for waiting, and welcome to Ascendis Pharma’s Stage II trainer test leading line week 52 information Phone call. [Operator Instructions]
I would certainly currently such as to hand the phone call over to Scott Smith, Ascendis Pharma’s CFO. Please go on.
Scott Smith
CFO, Exec VP & & Participant of Exec Board
Thanks a lot, driver, and thanks, everybody, for joining us on today’s phone call. Joining me are Jan Moller Mikkelsen, Head Of State and President; and Aimee Shu, Exec Vice Head Of State of Endocrine and Uncommon Illness Medical Sciences and Principal Medical Police Officer.
Prior to we start, I would love to advise you that this discussion will certainly consist of positive declarations that are planned to be covered under the risk-free harbor offered by the Exclusive Stocks Lawsuits Reform Act. Instances of such declarations might consist of, yet are not restricted to, declarations concerning our ongoing growth of TransCon CNP and TransCon Development Hormonal agent mix therapy, our pipe prospects and assumptions with